Labour drug pricing plan proposes new rewards for biopharmas beyond profits derived from exclusivity

The U.K.’s Labour Party plan to cut drug prices includes a proposed shake-up in the IP foundations underpinning drug development and commercialization by providing incentives for R&D other than patents.

The

Read the full 304 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE